Comparative Pharmacology
Head-to-head clinical analysis: PHENAPHEN W CODEINE NO 3 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENAPHEN W CODEINE NO 3 versus QDOLO.
PHENAPHEN W/ CODEINE NO. 3 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is an opioid agonist that binds to mu-opioid receptors, inhibiting adenylate cyclase and reducing cAMP production, leading to decreased neurotransmitter release and modulation of pain perception. Acetaminophen produces analgesia through central cyclooxygenase (COX) inhibition and activation of descending serotonergic pathways.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
One to two tablets (30-60 mg codeine phosphate/300-600 mg acetaminophen) orally every 4 hours as needed for pain, maximum 12 tablets per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Codeine: terminal elimination half-life is 2.5–3.5 hours in healthy adults; morphine: 1.5–4.5 hours; morphine-6-glucuronide: 2.5–4.5 hours. Half-life is prolonged in hepatic or renal impairment; in end-stage renal disease, half-life of codeine and metabolites may exceed 24 hours.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion of codeine and its metabolites (morphine, norcodeine, codeine-6-glucuronide, morphine-3-glucuronide, morphine-6-glucuronide). Approximately 80-90% of the dose is eliminated in urine within 24 hours, with about 10% as unchanged codeine, 10% as norcodeine, 10% as free and conjugated morphine, and the remainder as conjugated codeine and other metabolites. Fecal excretion accounts for less than 10%.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist